Enanta Pharmaceuticals, Inc. (ENTA): Price and Financial Metrics
GET POWR RATINGS... FREE!
ENTA POWR Grades
- Quality is the dimension where ENTA ranks best; there it ranks ahead of 74.41% of US stocks.
- The strongest trend for ENTA is in Quality, which has been heading up over the past 177 days.
- ENTA's current lowest rank is in the Stability metric (where it is better than 22.81% of US stocks).
ENTA Stock Summary
- Of note is the ratio of ENANTA PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; merely 9.01% of US stocks have a lower such ratio.
- ENTA's price/sales ratio is 12.78; that's higher than the P/S ratio of 90.88% of US stocks.
- With a year-over-year growth in debt of 374.07%, ENANTA PHARMACEUTICALS INC's debt growth rate surpasses 95.46% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to ENANTA PHARMACEUTICALS INC are QURE, RAPT, RNA, PTGX, and XBIT.
- Visit ENTA's SEC page to see the company's official filings. To visit the company's web site, go to www.enanta.com.
ENTA Valuation Summary
- ENTA's price/sales ratio is 12.3; this is 141.18% higher than that of the median Healthcare stock.
- Over the past 120 months, ENTA's price/earnings ratio has gone up 364.1.
Below are key valuation metrics over time for ENTA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ENTA | 2023-01-30 | 12.3 | 3.3 | -8.7 | -8.5 |
| ENTA | 2023-01-27 | 12.6 | 3.4 | -8.9 | -8.7 |
| ENTA | 2023-01-26 | 12.4 | 3.3 | -8.8 | -8.6 |
| ENTA | 2023-01-25 | 12.4 | 3.3 | -8.8 | -8.6 |
| ENTA | 2023-01-24 | 12.5 | 3.4 | -8.9 | -8.6 |
| ENTA | 2023-01-23 | 12.0 | 3.2 | -8.5 | -8.2 |
ENTA Growth Metrics
- The year over year net cashflow from operations growth rate now stands at -128.76%.
- The 4 year revenue growth rate now stands at 280.71%.
- The 4 year net cashflow from operations growth rate now stands at 1030.77%.
The table below shows ENTA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 86.16 | -84.782 | -121.755 |
| 2022-06-30 | 89.418 | -90.269 | -120.006 |
| 2022-03-31 | 91.563 | -90.173 | -112.33 |
| 2021-12-31 | 92.979 | -68.377 | -100.783 |
| 2021-09-30 | 97.074 | -69.996 | -78.996 |
| 2021-06-30 | 97.13 | -64.436 | -83.738 |
ENTA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ENTA has a Quality Grade of C, ranking ahead of 57.4% of graded US stocks.
- ENTA's asset turnover comes in at 0.206 -- ranking 196th of 682 Pharmaceutical Products stocks.
- GILD, ALT, and RDUS are the stocks whose asset turnover ratios are most correlated with ENTA.
The table below shows ENTA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.206 | 1 | -0.234 |
| 2021-03-31 | 0.193 | 1 | -0.207 |
| 2020-12-31 | 0.204 | 1 | -0.157 |
| 2020-09-30 | 0.242 | 1 | -0.083 |
| 2020-06-30 | 0.296 | 1 | -0.048 |
| 2020-03-31 | 0.354 | 1 | 0.017 |
ENTA Price Target
For more insight on analysts targets of ENTA, see our ENTA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $65.33 | Average Broker Recommendation | 1.7 (Moderate Buy) |
ENTA Stock Price Chart Interactive Chart >
ENTA Price/Volume Stats
| Current price | $52.94 | 52-week high | $79.50 |
| Prev. close | $52.50 | 52-week low | $37.59 |
| Day low | $51.85 | Volume | 98,700 |
| Day high | $53.17 | Avg. volume | 147,637 |
| 50-day MA | $47.14 | Dividend yield | N/A |
| 200-day MA | $51.10 | Market Cap | 1.11B |
Enanta Pharmaceuticals, Inc. (ENTA) Company Bio
Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses a chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. The company was founded in 1995 and is based in Watertown, Massachusetts.
Latest ENTA News From Around the Web
Below are the latest news stories about ENANTA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ENTA as an investment opportunity.
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022WATERTOWN, Mass., January 31, 2023--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2022 after the U.S. market closes on February 7, 2023. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its resea |
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare ConferenceWATERTOWN, Mass., January 06, 2023--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer, will provide an update across its pipeline of virology programs and plans for 2023 during Enanta’s presentation at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 3:00 p.m. PT. |
An Intrinsic Calculation For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Suggests It's 49% UndervaluedToday we will run through one way of estimating the intrinsic value of Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) by... |
Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare ConferenceWATERTOWN, Mass., January 03, 2023--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 at 3:00 p.m. PT. |
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2022 Earnings Call TranscriptEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2022 Earnings Call Transcript November 21, 2022 Enanta Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.27, expectations were $-1.35. Operator: Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal Fourth Quarter and Full Year Ended September 30, 2022 Financial Results Conference Call. At this time, all participants are in a […] |
ENTA Price Returns
| 1-mo | 6.43% |
| 3-mo | 27.75% |
| 6-mo | -20.38% |
| 1-year | -15.98% |
| 3-year | -5.11% |
| 5-year | -29.09% |
| YTD | 13.80% |
| 2022 | -37.79% |
| 2021 | 77.62% |
| 2020 | -31.85% |
| 2019 | -12.78% |
| 2018 | 20.71% |
Continue Researching ENTA
Want to do more research on Enanta Pharmaceuticals Inc's stock and its price? Try the links below:Enanta Pharmaceuticals Inc (ENTA) Stock Price | Nasdaq
Enanta Pharmaceuticals Inc (ENTA) Stock Quote, History and News - Yahoo Finance
Enanta Pharmaceuticals Inc (ENTA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...